BRPI0614021A2 - formulações farmacêuticas e métodos de uso - Google Patents
formulações farmacêuticas e métodos de uso Download PDFInfo
- Publication number
- BRPI0614021A2 BRPI0614021A2 BRPI0614021-1A BRPI0614021A BRPI0614021A2 BR PI0614021 A2 BRPI0614021 A2 BR PI0614021A2 BR PI0614021 A BRPI0614021 A BR PI0614021A BR PI0614021 A2 BRPI0614021 A2 BR PI0614021A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- gabapentin
- active ingredient
- independent
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64585705P | 2005-01-21 | 2005-01-21 | |
US60/645,857 | 2005-01-21 | ||
PCT/US2006/001887 WO2006078811A2 (en) | 2005-01-21 | 2006-01-20 | Pharmaceutical formulations and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0614021A2 true BRPI0614021A2 (pt) | 2011-03-01 |
Family
ID=36692870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0614021-1A BRPI0614021A2 (pt) | 2005-01-21 | 2006-01-20 | formulações farmacêuticas e métodos de uso |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1838291A4 (es) |
JP (1) | JP2008528494A (es) |
KR (1) | KR20070116588A (es) |
CN (1) | CN101137352A (es) |
AR (1) | AR062647A1 (es) |
AU (1) | AU2006206423A1 (es) |
BR (1) | BRPI0614021A2 (es) |
CA (1) | CA2595470A1 (es) |
IL (1) | IL184735A0 (es) |
MX (1) | MX2007008833A (es) |
TW (1) | TW200640497A (es) |
WO (1) | WO2006078811A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008077599A1 (en) | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS |
WO2009066325A1 (en) * | 2007-11-23 | 2009-05-28 | Lupin Limited | Controlled release pharmaceutical compositions of pregabalin |
CA2706596A1 (en) * | 2007-11-23 | 2009-05-28 | Protect Pharmaceutical Corporation | Tapentadol compositions |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
PT2661266T (pt) | 2011-01-07 | 2020-11-30 | Anji Pharma Us Llc | Terapias com base em ligandos do recetor quimiossensorial |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
LT2704698T (lt) * | 2011-05-05 | 2019-11-25 | Hennig Arzneimittel Gmbh&Co Kg | Vaisto forma, skirta aktyvių ingredientų kontroliuojamam atpalaidavimui |
KR101438546B1 (ko) * | 2011-08-26 | 2014-09-17 | 근화제약주식회사 | 프레가발린을 포함하는 서방성 제제 |
WO2013100873A1 (en) * | 2011-12-19 | 2013-07-04 | Mahmut Bilgic | Pharmaceutical formulation of pregabalin (particle size 300-2500 micrometer) |
EA201491335A1 (ru) | 2012-01-06 | 2015-04-30 | Элселикс Терапьютикс, Инк. | Бигуанидные композиции и способы лечения метаболических расстройств |
CN110693867A (zh) * | 2012-01-06 | 2020-01-17 | 埃尔舍利克斯治疗公司 | 用于治疗代谢性病症的组合物和方法 |
KR102221846B1 (ko) * | 2014-04-07 | 2021-02-26 | 영진약품 주식회사 | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 |
WO2016032000A1 (ja) * | 2014-08-29 | 2016-03-03 | わかもと製薬株式会社 | 乳酸菌含有組成物 |
CA3018328A1 (en) | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
WO2016187718A1 (en) * | 2015-05-26 | 2016-12-01 | Isa Odidi | Controlled extended release pregabalin |
TW201739455A (zh) | 2016-04-19 | 2017-11-16 | 菲林公司 | 菸鹼醯胺的口服醫藥組成物 |
US11026908B2 (en) * | 2016-07-17 | 2021-06-08 | Mapi Pharma Ltd. | Extended release dosage forms of pregabalin |
JP6919119B2 (ja) * | 2017-01-23 | 2021-08-18 | 日新製薬株式会社 | 3位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。 |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
CN112023032B (zh) * | 2020-09-14 | 2022-03-18 | 广东鼎信医药科技有限公司 | 一种含有消化酶的药物组合物及其制备方法 |
JP2024504902A (ja) | 2020-12-04 | 2024-02-02 | ラボラトリオス シラネス、エセ.ア.デ セ.べ. | 痛みに対するオピオイド鎮痛薬と抗てんかん薬のコーティングされた安定な固体医薬組成物 |
CN116898819B (zh) * | 2023-06-09 | 2024-02-06 | 则正(上海)生物科技有限公司 | 一种普瑞巴林缓释剂及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
EP0951278A2 (en) * | 1997-01-03 | 1999-10-27 | ELAN CORPORATION, Plc | Sustained release cisapride mini-tablet formulation |
FR2781793B1 (fr) * | 1998-08-03 | 2001-07-20 | Prographarm Lab | Procede de fabrication de granules de gabapentine enrobes |
WO2003079972A2 (en) * | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US20030224050A1 (en) * | 2002-01-04 | 2003-12-04 | Charles Chiao | Drug delivery system for sustained delivery of glipizide |
AU2006214454B2 (en) * | 2005-02-15 | 2011-05-19 | Jazz Pharmaceuticals, Inc. | Dosage form and method for sustained release of a substituted pyrazine compound |
-
2006
- 2006-01-20 WO PCT/US2006/001887 patent/WO2006078811A2/en active Application Filing
- 2006-01-20 JP JP2007552260A patent/JP2008528494A/ja active Pending
- 2006-01-20 AR ARP060100226A patent/AR062647A1/es not_active Application Discontinuation
- 2006-01-20 KR KR1020077019105A patent/KR20070116588A/ko not_active Application Discontinuation
- 2006-01-20 EP EP06718892A patent/EP1838291A4/en not_active Withdrawn
- 2006-01-20 MX MX2007008833A patent/MX2007008833A/es not_active Application Discontinuation
- 2006-01-20 CA CA002595470A patent/CA2595470A1/en not_active Abandoned
- 2006-01-20 TW TW095102217A patent/TW200640497A/zh unknown
- 2006-01-20 BR BRPI0614021-1A patent/BRPI0614021A2/pt not_active IP Right Cessation
- 2006-01-20 CN CNA2006800065476A patent/CN101137352A/zh active Pending
- 2006-01-20 AU AU2006206423A patent/AU2006206423A1/en not_active Abandoned
-
2007
- 2007-07-19 IL IL184735A patent/IL184735A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1838291A4 (en) | 2008-12-03 |
MX2007008833A (es) | 2008-03-25 |
AU2006206423A1 (en) | 2006-07-27 |
KR20070116588A (ko) | 2007-12-10 |
AR062647A1 (es) | 2008-11-26 |
JP2008528494A (ja) | 2008-07-31 |
EP1838291A2 (en) | 2007-10-03 |
IL184735A0 (en) | 2007-12-03 |
WO2006078811A3 (en) | 2007-03-01 |
TW200640497A (en) | 2006-12-01 |
CN101137352A (zh) | 2008-03-05 |
WO2006078811A2 (en) | 2006-07-27 |
CA2595470A1 (en) | 2006-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0614021A2 (pt) | formulações farmacêuticas e métodos de uso | |
EP0153104B1 (en) | Diffusion coated multiple-units dosage form | |
US6426091B1 (en) | Sustained-release theophylline tablet | |
JP2916978B2 (ja) | 放出開始制御型製剤 | |
ES2606463T3 (es) | Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada | |
EP0533297A1 (en) | Controlled-release pharmaceutical formulations | |
US20060182796A1 (en) | Taste masked pharmaceutical compositions | |
SK9899A3 (en) | Tramadol multiple unit formulations | |
MX2013010920A (es) | Metodos y composiciones para el tratamiento de transtorno por deficit de atencion. | |
JP5687185B2 (ja) | 多粒子系を含む二段階の放出プロフィールを有する固形経口剤 | |
JP2012514632A (ja) | 二段階放出型医薬懸濁剤 | |
TWI468191B (zh) | 有機化合物之調配物 | |
CN109475510A (zh) | 普瑞巴林的延长释放剂型 | |
TW201206501A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
US20150164920A1 (en) | Controlled release formulation comprising mesalamine | |
JPWO2019130749A1 (ja) | 新規微粒子コーティング(薬物含有中空粒子及びその製法) | |
ES2417330T3 (es) | Minicomprimidos farmacéuticos para la liberación sostenida de acetato de flecainida | |
ZA200600159B (en) | Novel solid pharmaceutical composition comprising amisulpride | |
CN114681392A (zh) | 一种缓释口服固体组合物 | |
CN106511291A (zh) | 一种盐酸阿考替胺缓释片剂及其制备方法 | |
CN114246836B (zh) | 一种普瑞巴林缓释片及其制备方法 | |
HUE030963T2 (en) | Sustained release formulations containing a 2-oxo-pyrrolidine derivative | |
EP3251661B1 (en) | Raloxifene sprinkle composition | |
JPS625915A (ja) | 塩酸ジルチアゼム徐放性製剤及びその製法 | |
TW200812579A (en) | Treatment of pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |